Phase I open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-6827 administered IV weekly X 3, repeated every 28 days, in subjects with refractory solid tumors.

Trial Profile

Phase I open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-6827 administered IV weekly X 3, repeated every 28 days, in subjects with refractory solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2009

At a glance

  • Drugs Verubulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Myrexis
  • Most Recent Events

    • 23 Nov 2009 New source identified and integrated M.D. Anderson Cancer Center, 2005-0091).
    • 30 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top